AR106488A1 - Antagonistas de receptores de cgrp - Google Patents

Antagonistas de receptores de cgrp

Info

Publication number
AR106488A1
AR106488A1 ARP160103295A ARP160103295A AR106488A1 AR 106488 A1 AR106488 A1 AR 106488A1 AR P160103295 A ARP160103295 A AR P160103295A AR P160103295 A ARP160103295 A AR P160103295A AR 106488 A1 AR106488 A1 AR 106488A1
Authority
AR
Argentina
Prior art keywords
cgrp
receiver antagonists
antagonists
cgrp receiver
cerebrovascular
Prior art date
Application number
ARP160103295A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Mason Jonathan
Pickworth Mark
Deflorian Francesca
Joanne Bucknell Sarah
Stuart Congreve Miles
Andrew Christopher John
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of AR106488A1 publication Critical patent/AR106488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP160103295A 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp AR106488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519195.0A GB201519195D0 (en) 2015-10-30 2015-10-30 CGRP Receptor Antagonists

Publications (1)

Publication Number Publication Date
AR106488A1 true AR106488A1 (es) 2018-01-17

Family

ID=55130447

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103295A AR106488A1 (es) 2015-10-30 2016-10-28 Antagonistas de receptores de cgrp

Country Status (13)

Country Link
US (2) US9802935B2 (OSRAM)
EP (1) EP3368536B1 (OSRAM)
JP (1) JP6874013B2 (OSRAM)
CN (1) CN108431005B (OSRAM)
AR (1) AR106488A1 (OSRAM)
AU (1) AU2016344688A1 (OSRAM)
BR (1) BR112018008419A2 (OSRAM)
CA (1) CA3002623A1 (OSRAM)
GB (1) GB201519195D0 (OSRAM)
IL (1) IL258893A (OSRAM)
SG (1) SG11201803380RA (OSRAM)
TW (1) TW201722952A (OSRAM)
WO (1) WO2017072722A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908430D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
KR20230128511A (ko) * 2021-01-05 2023-09-05 자이두스 라이프사이언시즈 리미티드 신규한 오토택신 억제제
WO2024046223A1 (zh) * 2022-08-30 2024-03-07 熙源安健医药（上海）有限公司 吲唑甲酰胺类衍生物及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
JP3483893B2 (ja) 1996-09-10 2004-01-06 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 修飾アミノ酸、これらの化合物を含む薬物及びそれらの調製方法
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
JP2002517444A (ja) 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
KR20050008790A (ko) 2002-06-05 2005-01-21 브리스톨-마이어스 스큅 컴퍼니 칼시토닌 유전자 관련 펩티드 수용체 길항제
US7842808B2 (en) * 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
AU2004222383B2 (en) * 2003-03-14 2009-10-01 Merck Sharp & Dohme Corp. Bicyclic anilide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AR046787A1 (es) 2003-12-05 2005-12-21 Bristol Myers Squibb Co Agentes antimigrana heterociclicos
EP1689493A4 (en) 2003-12-05 2008-04-23 Bristol Myers Squibb Co ANTAGONISTS OF THE CALCITONIN GENE RELATED PEPTIDE RECEPTOR
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20050233980A1 (en) 2004-04-20 2005-10-20 Boehringer Ingelheim International Gmbh CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2006006490A1 (ja) * 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
KR20070062997A (ko) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Ｃｇｒｐ 수용체 길항제
WO2006044449A2 (en) 2004-10-14 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
JP2008517916A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
KR20090021214A (ko) 2006-06-08 2009-02-27 베링거 인겔하임 인터내셔날 게엠베하 Ｃｇｒｐ-길항제에 의한 위장 장애의 치료
EP2225223B1 (de) * 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
TW201031665A (en) * 2009-02-04 2010-09-01 Gruenenthal Gmbh Substituted indole-compound
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8481546B2 (en) 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
US9174989B2 (en) 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists

Also Published As

Publication number Publication date
TW201722952A (zh) 2017-07-01
US9802935B2 (en) 2017-10-31
GB201519195D0 (en) 2015-12-16
IL258893A (en) 2018-06-28
CA3002623A1 (en) 2017-05-04
EP3368536A1 (en) 2018-09-05
US10259812B2 (en) 2019-04-16
JP6874013B2 (ja) 2021-05-19
BR112018008419A2 (pt) 2018-11-06
US20170121331A1 (en) 2017-05-04
JP2018532789A (ja) 2018-11-08
CN108431005A (zh) 2018-08-21
US20180009808A1 (en) 2018-01-11
EP3368536B1 (en) 2019-03-06
SG11201803380RA (en) 2018-05-30
CN108431005B (zh) 2020-12-25
AU2016344688A1 (en) 2018-05-17
WO2017072722A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
AR106488A1 (es) Antagonistas de receptores de cgrp
UY36684A (es) Agonistas de triazol del receptor apj
IL263686B (en) Treatment of amd using aav2 variant with aflibercept
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
HUE064141T2 (hu) Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
MX2018000880A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
BR112018008423A2 (pt) antagonistas do receptor cgrp
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
EP4034156A4 (en) COMBINATION THERAPY WITH CGRP ANTAGONISTS
LT3805220T (lt) Policikliniai karbamoilpiridono dariniai, skirti živ gydymui
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
EP3522912A4 (en) HETEROMULTIMERS OF TYPE I AND TYPE II RECEIVERS OF THE TGF-BETA SUPERFAMILY AND THEIR USES
EP3466996A4 (en) ORGANIC SILICON COMPOUND AND ADDITIVE FOR RUBBER AND RUBBER COMPOSITION THEREFOR
MX390653B (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.
IL282021A (en) Compounds and compositions for treating conditions associated with apj receptor activity
CL2018000290A1 (es) Antagonistas del receptor de cgrp
EP3697781C0 (en) MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS
AR106487A1 (es) Antagonistas de receptores de cgrp
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
EP3524640A4 (en) RESIN COMPOSITION AND MEMBRANE STRUCTURE THEREWITH
EP3506925C0 (en) USE OF CGRP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GLAUCOMA
KR102135648B9 (ko) 항독성 또는 항병원성 활성을 갖는 레오이딘 화합물 및 이의 용도

Legal Events

Date Code Title Description
FB Suspension of granting procedure